Shares of Longboard Pharmaceuticals Inc. are surging more than 51% Monday, boosted by H. Lundbeck’s $2.6 billion deal to acquire the California-based clinical-stage biopharmaceutical company.

Fmr LLC reduced its position in Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH – Free Report) by 1.5% during the 3rd quarter, ...

Longboard Pharmaceuticals ( (LBPH) ) has issued an update.

On December 2, 2024, Longboard Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: LBPH), was officially acquired by H. Lundbeck A/S, a Danish aktieselskab, as per an Agreement and Plan of Merger ...

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for neurological diseases. The company was founded on ...

Lundbeck has completed the acquisition of all outstanding shares of Longboard Pharmaceuticals, to bolster the neuro-rare disease sector.

Deal Dispatch: Altus Power, Motorsport Games Explore Options, True Value Goes Bankrupt, M&A Activity Lags S&P Global's Joe Mantone puts the latest M&A data in perspective and how deal pros might ...

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...